Stocktoria
uniQure N.V. QURE
uniQure N.V. (QURE) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $16.1M at a -1236.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-29 | HC Wainwright & Co. | Buy (main) |
| 2026-06-25 | Mizuho | Outperform (main) |
| 2026-06-18 | Barclays | Overweight (up) |
| 2026-06-18 | Goldman Sachs | Neutral (main) |
| 2026-06-18 | Leerink Partners | Outperform (main) |
| 2026-06-18 | RBC Capital | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.719 |
| Retained earnings / assets | -1.611 |
| EBIT / assets | -0.225 |
| Equity / liabilities | 0.318 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| QURE | uniQure N.V. | 4/9 | -1.71 | — | -40.6% |
| NEUP | Neuphoria Therapeutics Inc. | 4/9 | -16.04 | — | — |
| ZYBT | Zhengye Biotechnology Holding Ltd | 4/9 | 1.49 | — | -91.1% |
| CNTA | Centessa Pharmaceuticals plc | 4/9 | -1.11 | — | — |
| IRD | Opus Genetics, Inc. | 3/9 | -11.42 | — | +29.1% |
| ABUS | Arbutus Biopharma Corp | 3/9 | — | — | — |
| PYXS | Pyxis Oncology, Inc. | 2/9 | -16.86 | — | -14.2% |
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
FAQ
Is QURE financially healthy?
uniQure N.V.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does QURE pay a dividend?
No, uniQure N.V. does not currently pay a dividend.
How profitable is QURE?
In FY2025, uniQure N.V. had a net margin of -1236.0% and a return on equity of -100.0%.
What is the analyst price target for QURE?
The average Wall-Street price target for uniQure N.V. is $64.52, about 43.0% above the recent price, from 11 analysts (consensus: strong buy).
Is QURE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on uniQure N.V.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.